TELOMARKER
"Identification and characterization of novel human telomere-related biomarkers that aid cancer management by improving patient diagnosis, treatment selection, response monitoring, and drug development"
| Coordinatore | BRUNEL UNIVERSITY
Organization address
address: Kingston Lane contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.brunel.ac.uk/research/TeloMarker |
| Totale costo | 3˙683˙902 € |
| EC contributo | 2˙848˙490 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-02-01 - 2011-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
BRUNEL UNIVERSITY
Organization address
address: Kingston Lane contact info |
UK (UXBRIDGE) | coordinator | 0.00 |
| 2 |
ECOLE NORMALE SUPERIEURE DE LYON
Organization address
address: PARVIS RENE DESCARTES 15 contact info |
FR (Lyon) | participant | 0.00 |
| 3 |
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Organization address
address: BATIMENT CE 3316 STATION 1 contact info |
CH (LAUSANNE) | participant | 0.00 |
| 4 |
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Organization address
address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 contact info |
ES (MADRID) | participant | 0.00 |
| 5 |
UMEA UNIVERSITET
Organization address
address: UNIVERSITETOMRADET contact info |
SE (UMEA) | participant | 0.00 |
| 6 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 0.00 |
| 7 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 0.00 |
| 8 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Telomeres are DNA-nucleoprotein structures that protect the ends of human chromosomes through the formation of a ‘cap’ that prevents exonucleolytic degradation, inter- & intra-chromosomal fusion and subsequent chromosomal instability. Telomerase, the ribonucleoprotein enzyme that maintains linear chromosomal DNA ends by the addition of TTAGGG repeats, is completely repressed or present only at low, tightly regulated levels in normal human cells as a safeguard against cancer. Normally, telomere shortening in the absence of sufficient telomerase leads to telomere uncapping, activation of a DNA damage response, and either replicative senescence or apoptosis. Paradoxically, however, under certain conditions (when damage response pathways are defective, eg through p53 gene mutation) unchecked telomere shortening can generate a chronic genomic instability that drives and accelerates clonal evolution and cancer progression. As a result, telomeres are dysfunctional in human cancers. Individual protein components of the core telomere higher-order structure (known as the telosome, or the ‘shelterin’ complex) represent highly promising candidates for novel biomarkers of telomere dysfunction and human cancer progression. In this project (‘TeloMarker’) we have assembled the most experienced and talented scientists in telomere biology in the EU into a collaborative research consortium that will identify, characterize and validate novel telomere-related biomarkers. Biomarker discovery will be based both on known telosomal components and newly discovered affiliated proteins, as well as on telomerase and its recruitment factors. Novel telomere-related cancer biomarkers promise radically to improve early diagnosis, patient treatment selection, prognostic evaluation, and outcome monitoring, as well as furnishing new molecular targets for the development of novel small molecule anti-cancer drugs.'